福齐夫定替酯
|
|
|
- CAS号:
- 141790-23-0
- 英文名:
- Fozivudine
- 英文别名:
- FZT;BM-211290;Fozivudine;W-09726867;HDP-990002;HDP-99.0002;fozivudine tidoxil;(2S,3S,5R)-3-azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl (2-decoxy-3-dodecylsulfanylpropyl) hydrogen phosphate
- 中文名:
- 福齐夫定替酯
- 中文别名:
- 福齐夫定替酯;化合物 T27354
- CBNumber:
- CB51178819
- 分子式:
- C35H64N5O8PS
- 分子量:
- 745.958
- MOL File:
- 141790-23-0.mol
|
|
|
福齐夫定替酯性质、用途与生产工艺
Fozivudine tidoxil (BM-211290) 是具有口服活性的硫醚脂质-齐多夫定 (lipid-zidovudine) 偶联物，具有抗 HIV 活性的。Fozivudine tidoxil 是 NRTI 家族成员，在细胞内病毒复制过程中被掺入到新合成的 DNA 链中，并且不可逆地结合病毒 RT，从而破坏病毒的逆转录。
Fozivudine tidoxil (BM-211290) is a member of the nucleoside analogue reverse transcriptase inhibitor (NRTI) family.
Fozivudine tidoxil (BM-211290; 45 mg/kg; PO; twice daily; one day before FIV challenge for a total of six weeks) is effective at lowering plasma- and cell-associated viremia at two weeks post-FIV infection.
|
Animal Model:
|
Specific pathogen-free cats at 6 months of age
|
|
Dosage:
|
45 mg/kg
|
|
Administration:
|
PO; twice daily; one day before FIV challenge for a total of six weeks
|
|
Result:
|
Effective at lowering plasma- and cell-associated viremia at two weeks post-feline immunodeficiency virus (FIV) infection with a trend toward lower plasma- and cell- associated viremia at four and six weeks post-infection (PI).
|
福齐夫定替酯
上下游产品信息
上游原料
下游产品
141790-23-0, 福齐夫定替酯 相关搜索:
- 化合物 T27354
- 福齐夫定替酯
- 141790-23-0
- W-09726867
- HDP-990002
- HDP-99.0002
- FZT
- BM-211290
- (2S,3S,5R)-3-azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl (2-decoxy-3-dodecylsulfanylpropyl) hydrogen phosphate
- fozivudine tidoxil
- Fozivudine